Swedish medtech company Capitainer has raised just over 5.7 million USD to expand and commercialise its unique self-sampling technology for remote healthcare solutions and personalised medicine. The funding will be used to increase production capacity, develop new products, and intensify sales and marketing efforts. The investment round was led by Sciety and the network Sciety Venture Partners.
Capitainer’s self-sampling technology enables patients to take precise blood samples using a special card, which is then sent for analysis by standard post without the need for refrigeration or special packaging. Capitainer is experiencing growing demand for its products in several markets and has recently partnered with several distributors.
Capitainer plans to establish itself as the leading supplier of self-sampling solutions with market-leading clinical accuracy. The company’s commitment to innovation and rapid growth has attracted continued support from leading investment company Sciety and its network Sciety Venture Partners, who have invested in Capitainer for the third time since 2019.
“Thanks to the continued support from Sciety, we are able to accelerate our growth and expand our production capacity. Their expertise in life science combined with industry connections will be valuable for Capitainer as we continue to advance. We are confident that our self-sampling technology will become a game-changer in the healthcare industry, providing patients with greater convenience and accessibility while ensuring precise results,” said Christopher Aulin, CEO at Capitainer.
“We are excited to invest in Capitainer again and support their vision of revolutionising blood sample collection. Capitainer’s innovative platform has the potential to significantly impact personalised medicine and remote healthcare, which is perfectly in line with Sciety’s vision to bring healthcare breakthroughs to people worldwide,” commented Andreas Lindblom, Managing Partner at Sciety.